Skip to main content
SpringerLink
Log in

Single and dual blockade of the renin-angiotensin system in high-risk patients without heart failure: Lessons from ONTARGET

  • Invited Commentary
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547–1559.

    Article  Google Scholar 

  2. The Heart Outcomes Prevention Evaluation study investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153.

    Article  Google Scholar 

  3. Fox KM; European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators: Efficacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782–788.

    Article  PubMed  CAS  Google Scholar 

  4. The PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351:2058–2068.

    Article  Google Scholar 

  5. Dagenais GR, Pogue J, Fox K, et al.: Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006, 368:581–588.

    Article  PubMed  CAS  Google Scholar 

  6. Biollaz J, Brunner HR, Gavras I, et al.: Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982, 4:966–972.

    Article  PubMed  CAS  Google Scholar 

  7. Lakhdar R, Al-Mallah MH, Lanfear DE: Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008, 14:181–188.

    Article  PubMed  CAS  Google Scholar 

  8. Pfeffer MA, McMurray JJV, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906.

    Article  PubMed  CAS  Google Scholar 

  9. Cohn JN, Tognoni G: A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.

    Article  PubMed  CAS  Google Scholar 

  10. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensinconverting enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.

    Article  PubMed  CAS  Google Scholar 

  11. McMurray JV: ACE inhibitors in cardiovascular disease—unbeatable? N Engl J Med 2008, 358:1616–1616.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Research Unit-Preventive Cardiology, Department of Cardiology, Hospital Santa Maria della Misericordia, 06156, Perugia, Italy

    Paolo Verdecchia

Authors
  1. Paolo Verdecchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabio Angeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni Mazzotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiara Dembech
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gianpaolo Reboldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Verdecchia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verdecchia, P., Angeli, F., Mazzotta, G. et al. Single and dual blockade of the renin-angiotensin system in high-risk patients without heart failure: Lessons from ONTARGET. Curr Cardio Risk Rep 2, 417–419 (2008). https://doi.org/10.1007/s12170-008-0073-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-008-0073-5

Keywords

Search

Navigation